Interaction of serum ferritin and body mass index in patients with chronic hepatitis B: Improved prediction of cirrhosis
Sanjoy Paul, Kevin O'Regan, Andrew St John, Katherine Stuart, Darrell Crawford – 17 September 2012
Toll‐like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice
Kouichi Miura, Ling Yang, Nico van Rooijen, David A. Brenner, Hirohide Ohnishi, Ekihiro Seki – 17 September 2012 – Innate immune signaling associated with Toll‐like receptors (TLRs) is a key pathway involved in the progression of nonalcoholic steatohepatitis (NASH). Here we show that both TLR2 and palmitic acid are required for activation of the inflammasome, interleukin (IL)‐1α, and IL‐1β, resulting in the progression of NASH. Wild‐type (WT) and TLR2−/− mice were fed a choline‐deficient amino acid–defined (CDAA) diet for 22 weeks to induce NASH.
Preserving the morphology and evaluating the quality of liver grafts by hypothermic machine perfusion: A proof‐of‐concept study using discarded human livers
Diethard Monbaliu, Qiang Liu, Louis Libbrecht, Rita De Vos, Katrien Vekemans, Charlotte Debbaut, Olivier Detry, Tania Roskams, Jos van Pelt, Jacques Pirenne – 17 September 2012 – The wider use of livers from expanded criteria donors and donation after circulatory death donors may help to improve access to liver transplantation. A prerequisite for safely using these higher risk livers is the development of objective criteria for assessing their condition before transplantation.
Donor polymorphisms of toll‐like receptor 4 associated with graft failure in liver transplant recipients
William S. Oetting, Weihua Guan, David P. Schladt, Robert E. Leduc, Pamala A. Jacobson, Arthur J. Matas, Srinath Chinnakotla, Bernd Schröppel, Barbara T. Murphy, Ajay K. Israni – 15 September 2012 – There have been many reports showing significant associations between recipient genetic variants and allograft outcomes, including acute rejection and graft failure, but less is known about the contribution of the donor genotype.
Declining liver utilization for transplantation in the United States and the impact of donation after cardiac death
Eric S. Orman, A. Sidney Barritt, Stephanie B. Wheeler, Paul H. Hayashi – 11 September 2012 – Worsening donor liver quality resulting in decreased organ utilization may be contributing to the recent decline in liver transplants nationally. We sought to examine trends in donor liver utilization and the relationship between donor characteristics and nonuse. We used the United Network for Organ Sharing database to review all deceased adult organ donors in the United States from whom at least 1 solid organ was transplanted into a recipient. Trends in donor characteristics were examined.
Factors that affect deceased donor liver transplantation rates in the United States in addition to the model for end‐stage liver disease score
Pratima Sharma, Douglas E. Schaubel, Emily E. Messersmith, Mary K. Guidinger, Robert M. Merion – 11 September 2012 – Under an ideal implementation of Model for End‐Stage Liver Disease (MELD)–based liver allocation, the only factors that would predict deceased donor liver transplantation (DDLT) rates would be the MELD score, blood type, and donation service area (DSA). We aimed to determine whether additional factors are associated with DDLT rates in actual practice.
TRAIL but not FasL and TNFα, regulates IL‐33 expression in murine hepatocytes during acute hepatitis
Muhammad Imran Arshad, Claire Piquet‐Pellorce, Annie L'Helgoualc'h, Michel Rauch, Solène Patrat‐Delon, Frédéric Ezan, Catherine Lucas‐Clerc, Sabrina Nabti, Agnès Lehuen, Francisco Javier Cubero, Jean‐Philippe Girard, Christian Trautwein, Michel Samson – 10 September 2012 – Interleukin (IL)‐33, a member of the IL‐1 cytokine family, positively correlates with acute hepatitis and chronic liver failure in mice and humans. IL‐33 is expressed in hepatocytes and is regulated by natural killer T (NKT) cells during concanavalin A (ConA)‐induced acute liver injury.
Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate
George A. Diaz, Lauren S. Krivitzky, Masoud Mokhtarani, William Rhead, James Bartley, Annette Feigenbaum, Nicola Longo, William Berquist, Susan A. Berry, Renata Gallagher, Uta Lichter‐Konecki, Dennis Bartholomew, Cary O. Harding, Stephen Cederbaum, Shawn E. McCandless, Wendy Smith, Gerald Vockley, Stephen A. Bart, Mark S. Korson, David Kronn, Roberto Zori, J. Lawrence Merritt, Sandesh C.S. Nagamani, Joseph Mauney, Cynthia LeMons, Klara Dickinson, Tristen L. Moors, Dion F. Coakley, Bruce F.
Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate
George A. Diaz, Lauren S. Krivitzky, Masoud Mokhtarani, William Rhead, James Bartley, Annette Feigenbaum, Nicola Longo, William Berquist, Susan A. Berry, Renata Gallagher, Uta Lichter‐Konecki, Dennis Bartholomew, Cary O. Harding, Stephen Cederbaum, Shawn E. McCandless, Wendy Smith, Gerald Vockley, Stephen A. Bart, Mark S. Korson, David Kronn, Roberto Zori, J. Lawrence Merritt, Sandesh C.S. Nagamani, Joseph Mauney, Cynthia LeMons, Klara Dickinson, Tristen L. Moors, Dion F. Coakley, Bruce F.
Intrahepatic cholestasis of pregnancy levels of sulfated progesterone metabolites inhibit farnesoid X receptor resulting in a cholestatic phenotype
Shadi Abu‐Hayyeh, Georgia Papacleovoulou, Anita Lövgren‐Sandblom, Mehreen Tahir, Olayiwola Oduwole, Nurul Akmal Jamaludin, Sabiha Ravat, Vanya Nikolova, Jenny Chambers, Clare Selden, Myrddin Rees, Hanns‐Ulrich Marschall, Malcolm G. Parker, Catherine Williamson – 7 September 2012 – Intrahepatic cholestasis of pregnancy (ICP) is the most prevalent pregnancy‐specific liver disease and is associated with an increased risk of adverse fetal outcomes, including preterm labor and intrauterine death.